Search research articles
Contact Us
Filters
Showing results (111-120 of 144) with videos related to
Page
of 15
Sort By:
European Journal of Haematology
|
October 24, 1997
Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK)
A Lohri, B van Hille, M Bacchi, et al.
International Journal of Cancer
|
December 1, 1994
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer
A E Oberli-Schrämmli, F Joncourt, M Stadler, et al.
British Journal of Cancer
|
August 1, 1994
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
T Cerny, S Kaplan, N Pavlidis, et al.
Onkologie
|
May 15, 2002
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
S Pampallona, E Von Rohr, B Van Wegberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1995
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, P Alberto, C Hürny, et al.
British Journal of Haematology
|
September 1, 1993
Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemia
F Joncourt, A Oberli, S M Redmond, et al.
Schweizerische Medizinische Wochenschrift
|
February 11, 1995
[Participation in multicenter studies as quality control in the therapy of Hodgkin disease: an interim report]
A Lohri, S Leyvraz, T Cerny, et al.
Schweizerische Medizinische Wochenschrift
|
November 24, 1998
[2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research]
R A Sperb, A von Rohr, D Ratschiller, et al.
International Journal of Cancer
|
September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)
T Cerny, M F Fey, R Oppliger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1995
Phase I clinical and pharmacokinetic study of oral etoposide phosphate
C Sessa, M Zucchetti, T Cerny, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 144) with videos related to
Sort By:
Page
of 15
European Journal of Haematology
|
October 24, 1997
Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK)
A Lohri, B van Hille, M Bacchi, et al.
International Journal of Cancer
|
December 1, 1994
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer
A E Oberli-Schrämmli, F Joncourt, M Stadler, et al.
British Journal of Cancer
|
August 1, 1994
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
T Cerny, S Kaplan, N Pavlidis, et al.
Onkologie
|
May 15, 2002
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
S Pampallona, E Von Rohr, B Van Wegberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1995
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, P Alberto, C Hürny, et al.
British Journal of Haematology
|
September 1, 1993
Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemia
F Joncourt, A Oberli, S M Redmond, et al.
Schweizerische Medizinische Wochenschrift
|
February 11, 1995
[Participation in multicenter studies as quality control in the therapy of Hodgkin disease: an interim report]
A Lohri, S Leyvraz, T Cerny, et al.
Schweizerische Medizinische Wochenschrift
|
November 24, 1998
[2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research]
R A Sperb, A von Rohr, D Ratschiller, et al.
International Journal of Cancer
|
September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)
T Cerny, M F Fey, R Oppliger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1995
Phase I clinical and pharmacokinetic study of oral etoposide phosphate
C Sessa, M Zucchetti, T Cerny, et al.
Page
of 15